Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May 3:12:645989.
doi: 10.3389/fimmu.2021.645989. eCollection 2021.

Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure

Verena Keitel  1 , Johannes Georg Bode  1 , Torsten Feldt  1 , Andreas Walker  2 , Lisa Müller  2 , Anselm Kunstein  1 , Caroline Klindt  1 , Alexander Killer  1 , Tina Senff  2 , Jörg Timm  2 , Philipp Ostermann  2 , Maximilian Damagnez  2 , Nadine Lübke  2 , Ortwin Adams  2 , Heiner Schaal  2 , Gerald Antoch  3 , Jennifer Neubert  4 , Philipp Albrecht  5 , Sven Meuth  5 , Saskia Elben  5 , Annemarie Mohring  6 , Johannes C Fischer  7 , Edwin Bölke  8 , Manfred Hoenig  9 , Ansgar S Schulz  9 , Tom Luedde  1 , Björn Jensen  1
Affiliations
Case Reports

Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure

Verena Keitel et al. Front Immunol. .

Abstract

We describe the unique disease course and cure of SARS-CoV-2 infection in a patient with SCID and graft failure. In absence of a humoral immune response, viral clearance was only achieved after transfusion of convalescent plasma. This observation underscores the necessity of the humoral immune response for SARS-CoV-2 clearance.

Keywords: SARS-CoV-2; convalescent plasma; humoral immune response; remdesivir; severe combined immunodeficiency.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Chest CT scans on day 3 after admission (A) without signs of COVID-19 and day 34 (B) showing COVID-19 pneumonia.
Figure 2
Figure 2
SARS-CoV-2 viral concentration (VC) in nasopharyngeal swabs (in red) and spike specific SARS-CoV-2 antibody titers over time (in blue). Cell culture was used to determine viral replication as well as presence of neutralizing antibodies (Ab). Application of remdesivir (RDV) over 10 days is depicted in grey. Application of convalescent plasma from 2 different donors is depicted as dotted green lines (light green = 3 units from donor-1; dark green = 3 units from donor-2).
See this image and copyright information in PMC

References

    1. Notarangelo LD, Kim MS, Walter JE, Lee YN. Human RAG Mutations: Biochemistry and Clinical Implications. Nat Rev Immunol (2016) 16(4):234–46. 10.1038/nri.2016.28 - DOI - PMC - PubMed
    1. Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe Combined Immunodeficiencies and Related Disorders. Nat Rev Dis Primers (2015) 1:15061. 10.1038/nrdp.2015.61 - DOI - PubMed
    1. Goodall JW, Reed TAN, Ardissino M, Bassett P, Whittington AM, Cohen DL, et al. Risk Factors for Severe Disease in Patients Admitted With COVID-19 to a Hospital in London, England: A Retrospective Cohort Study. Epidemiol Infect (2020) 148:e251. 10.1017/S0950268820002472 - DOI - PMC - PubMed
    1. Kim L, Garg S, O’Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified Through the U.S. Coronavirus Disease 2019 (Covid-19)-Associated Hospitalization Surveillance Network (Covid-Net). Clin Infect Dis (2020). 10.1093/cid/ciaa1012 - DOI - PMC - PubMed
    1. Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case Study: Prolonged Infectious SARS-Cov-2 Shedding From an Asymptomatic Immunocompromised Individual With Cancer. Cell (2020) 183:1901–12. 10.1016/j.cell.2020.10.049 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances